Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) General Information
Description
GX301 is a clinical-stage therapeutic vaccine based in Torino, Italy. The vaccine is composed of multiple peptides and adjuvants and is designed to induce potent immune responses that are specific for cancer cells through the activation of both CD4+ and CD8+ T lymphocytes.
Contact Information
Corporate Office
- Turin
- Italy
Corporate Office
- Turin
- Italy
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) FAQs
-
Where is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) headquartered?
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) is headquartered in Turin, Italy.
-
What industry is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) in?
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)’s primary industry is Buildings and Property.
-
Is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) a private or public company?
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) is a Private company.
-
What is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)’s current revenue?
The current revenue for Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) is .
-
Who are Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)’s investors?
Genovax has invested in Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin).
-
When was Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) acquired?
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) was acquired on 03-Dec-2012.
-
Who acquired Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)?
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) was acquired by Mediolanum Farmaceutici.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process